TY - JOUR
T1 - Suppression of β-catenin by antisense oligomers augments tumor response to isolated limb perfusion in a rodent model of adenomatous polyposis coli-mutant colon cancer
AU - Canter, Robert J.
AU - Kesmodel, Susan B.
AU - Heitjan, Daniel F.
AU - Veeramachaneni, Nirmal K.
AU - Mokadam, Nahush A.
AU - Drebin, Jeffrey A.
AU - Fraker, Douglas L.
N1 - Funding Information:
Supported by the Georgene S. Harmelin Endowment Fund (D.L.F.) and by grants from the National Institutes of Health and the Burroughs Wellcome Fund (J.A.D.).
PY - 2005/9
Y1 - 2005/9
N2 - Background: Isolated hepatic perfusion has been used in patients with colorectal cancer (CRC) metastatic to the liver. We sought to determine whether perfusion with antisense oligodeoxynucleotides results in the downregulation of β-catenin and whether this improves tumor response to isolated limb perfusion (ILP) in a heterotopic model of human CRC. Methods: Adenomatous polyposis coli-mutant human CRC xenografts were implanted into athymic rats. Animals were randomized to the following groups: (1) no treatment, (2) control ILP, (3) melphalan ILP, (4) ILP with antisense specific for β-catenin, (5) ILP with nonspecific antisense, and (6) melphalan plus β-catenin-specific antisense ILP. Tumor response and Western blot analysis of protein expression were evaluated. Results: The maximal decrease (mean ± SE) in tumor volume was 0% ± 10% for no treatment, 19% ± 14% for control ILP, 58% ± 3% for melphalan ILP, 58% ± 9% for β-catenin-specific ILP, 13% ± 19% for nonspecific antisense ILP, and 73% ± 6% for melphalan plus β-catenin-specific ILP (P < .05 for melphalan ILP, β-catenin-specific ILP, and melphalan plus antisense ILP). Tumor regrowth was delayed for 6 days after control ILP, 24 days after melphalan ILP, 20 days after β-catenin-specific ILP, 10 days after nonspecific antisense ILP, and 60 days after melphalan plus β-catenin-specific ILP (P < .05 for melphalan plus β-catenin-specific ILP compared with all others). Western blotting revealed prolonged suppression of β-catenin expression after β-catenin-specific ILP. Conclusions: Short-term β-catenin antisense treatment improves tumor response rates after ILP in a rodent model of human CRC.
AB - Background: Isolated hepatic perfusion has been used in patients with colorectal cancer (CRC) metastatic to the liver. We sought to determine whether perfusion with antisense oligodeoxynucleotides results in the downregulation of β-catenin and whether this improves tumor response to isolated limb perfusion (ILP) in a heterotopic model of human CRC. Methods: Adenomatous polyposis coli-mutant human CRC xenografts were implanted into athymic rats. Animals were randomized to the following groups: (1) no treatment, (2) control ILP, (3) melphalan ILP, (4) ILP with antisense specific for β-catenin, (5) ILP with nonspecific antisense, and (6) melphalan plus β-catenin-specific antisense ILP. Tumor response and Western blot analysis of protein expression were evaluated. Results: The maximal decrease (mean ± SE) in tumor volume was 0% ± 10% for no treatment, 19% ± 14% for control ILP, 58% ± 3% for melphalan ILP, 58% ± 9% for β-catenin-specific ILP, 13% ± 19% for nonspecific antisense ILP, and 73% ± 6% for melphalan plus β-catenin-specific ILP (P < .05 for melphalan ILP, β-catenin-specific ILP, and melphalan plus antisense ILP). Tumor regrowth was delayed for 6 days after control ILP, 24 days after melphalan ILP, 20 days after β-catenin-specific ILP, 10 days after nonspecific antisense ILP, and 60 days after melphalan plus β-catenin-specific ILP (P < .05 for melphalan plus β-catenin-specific ILP compared with all others). Western blotting revealed prolonged suppression of β-catenin expression after β-catenin-specific ILP. Conclusions: Short-term β-catenin antisense treatment improves tumor response rates after ILP in a rodent model of human CRC.
KW - Adenomatous polyposis coli
KW - Hepatic metastases
KW - Isolated limb perfusion
KW - β-Catenin antisense
UR - http://www.scopus.com/inward/record.url?scp=23944453880&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=23944453880&partnerID=8YFLogxK
U2 - 10.1245/ASO.2005.10.005
DO - 10.1245/ASO.2005.10.005
M3 - Article
C2 - 16132380
AN - SCOPUS:23944453880
SN - 1068-9265
VL - 12
SP - 733
EP - 742
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 9
ER -